SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess
of $150,000 From Investment in Vanda Pharmaceuticals, Inc. to Contact Brower
Piven Before the August 26, 2013 Lead Plaintiff Deadline -- VNDA
STEVENSON, Md., July 1, 2013 (GLOBE NEWSWIRE) -- Brower Piven, A Professional
Corporation announces that a class action lawsuit has been commenced in the
United States District Court for the District of Columbia on behalf of
purchasers of Vanda Pharmaceuticals, Inc. ("Vanda" or the "Company")
(Nasdaq:VNDA) securities during the period between December 18, 2012 and June
18, 2013, inclusive ("Class Period").
If you have suffered a net loss from investment in Vanda securities purchased
on or after December 18, 2012, and held through June 19, 2013, you may obtain
additional information about this lawsuit and your ability to become a lead
plaintiff by contacting Brower Piven at www.browerpiven.com, by email at
email@example.com, by calling 410/415-6616, or at Brower Piven, A
Professional Corporation, 1925 Old Valley Road, Stevenson, Maryland 21153.
Attorneys at Brower Piven have combined experience litigating securities and
class action cases of over 60 years.
No class has yet been certified in the above action. Members of the Class will
be represented by the lead plaintiff and counsel chosen by the lead plaintiff.
If you wish to choose counsel to represent you and the Class, you must apply
to be appointed lead plaintiff no later than August 26, 2013 and be selected
by the Court. The lead plaintiff will direct the litigation and participate in
important decisions including whether to accept a settlement and how much of a
settlement to accept for the Class in the action. The lead plaintiff will be
selected from among applicants claiming the largest loss from investment in
the Company during the Class Period.
The complaint accuses the defendants of violations of the Securities Exchange
Act of 1934 by virtue of the defendants' failure to disclose during the Class
Period that, in the middle of its Phase III studies for the use of the
compound tasimelteon for the treatment of a rare circadian rhythm sleep
disorder ("Non-24"), the Company unilaterally changed the primary endpoint of
nighttime total sleep to an endpoint never used in a sleep-drug clinical trial
and that was not endorsed by the U.S. Food and Drug Administration because the
Company possessed data suggesting that the original nighttime total sleep
primary endpoint was not going to be met. According to the complaint,
following a June 19, 2013 article that appeared in The Street raising doubts
about the quality and efficacy of Vanda's clinical trial procedure and test
data, including multiple changes in the primary endpoint during the Phase III
trials, the value of Vanda shares declined significantly.
If you choose to retain counsel, you may retain Brower Piven without financial
obligation or cost to you, or you may retain other counsel of your choice. You
need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven
Brower Piven, A Professional Corporation
Press spacebar to pause and continue. Press esc to stop.